Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The current ratio is N/A as of Tuesday, October 6, 2026.
CURRENT RATIO
N/A
Market Cap
$1.02B
Current Ratio
1.44
TTM Avg
1.13
3Y Avg
1.10
5Y Avg
1.10
Market Cap
$998.12M
Current Ratio
15.08
TTM Avg
22.50
3Y Avg
27.08
5Y Avg
27.08
Market Cap
$993.23M
Current Ratio
6.55
TTM Avg
7.96
3Y Avg
7.82
5Y Avg
9.82
Market Cap
$984.16M
Current Ratio
5.04
TTM Avg
3.47
3Y Avg
3.89
5Y Avg
3.30
Market Cap
$982.85M
Current Ratio
16.33
TTM Avg
11.68
3Y Avg
16.13
5Y Avg
16.13
Market Cap
$1.03B
Current Ratio
3.40
TTM Avg
1.85
3Y Avg
2.70
5Y Avg
2.88
Market Cap
$1.04B
Current Ratio
6.04
TTM Avg
6.28
3Y Avg
6.71
5Y Avg
10.27
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Latigo Biotherapeutics Inc. (LTGO) | $1.01B | N/A | N/A | N/A | N/A |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | 1.44 | 1.13 | 1.10 | 1.10 |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $998.12M | 15.08 | 22.50 | 27.08 | 27.08 |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $993.23M | 6.55 | 7.96 | 7.82 | 9.82 |
| MeiraGTx Holdings plc (MGTX)vs › | $991.26M | 3.76 | 1.39 | 1.76 | 2.46 |
| Pacira BioSciences, Inc. (PCRX)vs › | $984.16M | 5.04 | 3.47 | 3.89 | 3.30 |
| Aktis Oncology, Inc. (AKTS)vs › | $982.85M | 16.33 | 11.68 | 16.13 | 16.13 |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.03B | 3.40 | 1.85 | 2.70 | 2.88 |
| Castle Biosciences, Inc. (CSTL)vs › | $1.04B | 6.04 | 6.28 | 6.71 | 10.27 |
| Immatics N.V. (IMTX)vs › | $1.04B | 7.54 | 10.49 | 6.85 | 5.34 |
Current Ratio
N/A
Quick Ratio
N/A
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
